Identifying genetic risks for complications in childhood cancer patients in Switzerland
Genetic Risks for Childhood Cancer Complications in Switzerland
This study is trying to find out if certain genetic differences can help explain the complications that childhood cancer patients in Switzerland might face after their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | N/A to 21 Years |
| Sex | All |
| Sponsor | University Hospital, Geneva Academic / other |
| Locations | 1 site (Geneva) |
| Trial ID | NCT04702321 on ClinicalTrials.gov |
What this trial studies
The GECCOS project aims to identify genetic variants linked to complications arising from childhood cancer treatments by analyzing germline genetic samples and clinical data from Swiss childhood cancer patients. This observational study utilizes data from the Germline DNA Biobank for Childhood Cancer and Blood Disorders in Switzerland, focusing on understanding how genetic differences can influence the severity and type of complications experienced by these patients. By correlating genetic information with clinical outcomes, the project seeks to enhance personalized care for childhood cancer survivors. This nationwide analysis has not been previously conducted in Switzerland.
Who should consider this trial
Good fit: Ideal candidates for this study are childhood cancer patients registered in the Swiss Childhood Cancer Registry who have consented to participate in the biobank.
Not a fit: Patients who do not have a genetic predisposition to complications or those who have not consented to the biobank will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved personalized treatment strategies for childhood cancer patients, minimizing complications and enhancing their quality of life.
How similar studies have performed: While this approach is novel in Switzerland, similar studies in other countries have shown success in linking genetic variants to treatment complications in childhood cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Registered in the Swiss Childhood Cancer Registry (SCCR) since 1976; AND 2. consented to the BaHOP (host biobank for the BISKIDS Biobanking project); AND 3. diagnosed with cancer according to the International Classification of Childhood Cancer, version 3, ICCC-3, or Langerhans cell histiocytosis (LCH) before age 21 years. Exclusion Criteria: 1. Lacking written consent signed by participant and/ or their legal representative to participate in the BaHOP (where applicable); OR 2. died after study participation and declined use of their samples and data after their death in the original consent for BaHOP (as indicated on the BaHOP consent).
Where this trial is running
Geneva
- University Hospital of Geneva — Geneva, Switzerland (Recruiting)
Study contacts
- Study coordinator: Marc Ansari, Prof
- Email: Marc.Ansari@hcuge.ch
- Phone: +41 79 553 61 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.